Merck & Co Inc (MRK): Today's Featured Drugs Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Merck ( MRK) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole was unchanged today. By the end of trading, Merck rose $0.52 (1.1%) to $47.87 on light volume. Throughout the day, 10,566,903 shares of Merck exchanged hands as compared to its average daily volume of 16,635,600 shares. The stock ranged in a price between $47.11-$48.07 after having opened the day at $47.27 as compared to the previous trading day's close of $47.35. Other companies within the Drugs industry that increased today were: Bacterin International Holdings ( BONE), up 17.1%, Tesaro ( TSRO), up 13.2%, Oxygen Biotherapeutics ( OXBT), up 12.4% and Enanta Pharmaceuticals ( ENTA), up 11.3%.
  • EXCLUSIVE OFFER: Jim Cramer's Protege, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. Merck has a market cap of $144.7 billion and is part of the health care sector. The company has a P/E ratio of 24.0, above the S&P 500 P/E ratio of 17.7. Shares are up 15.7% year to date as of the close of trading on Thursday.

TheStreet Ratings rates Merck as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, solid stock price performance, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front, Dyax Corporation ( DYAX), down 34.9%, Atossa Genetics ( ATOS), down 7.9%, Amicus Therapeutics ( FOLD), down 7.9% and China Pharma ( CPHI), down 7.7% , were all laggards within the drugs industry with Vertex Pharmaceuticals ( VRTX) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

null

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%